A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer
about
Progress and problems with the use of suicide genes for targeted cancer therapyEnhancement of adenovirus delivery after ultrasound-stimulated therapy in a cancer model.Combinatorial peptide libraries: mining for cell-binding peptides.Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Somatostatin receptor based imaging and radionuclide therapy.Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovirPreclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancerTargeting adenoviral vectors for enhanced gene therapy of uterine leiomyomasLeveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineEnhancement of BMP-2 induced bone regeneration by SDF-1α mediated stem cell recruitment.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Oncolytic vaccinia virotherapy for endometrial cancerUterine fibroids: clinical manifestations and contemporary management.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Targeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma.Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.Enzyme/Prodrug Systems for Cancer Gene Therapy.Stem cell attraction via SDF-1α expressing fat tissue grafts.VSV based virotherapy in ovarian cancer: the past, the present and …future?CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates.Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.
P2860
Q28262370-9A171573-9089-4664-9C18-99E5B1BA0863Q30439332-D62B11E6-C47B-4A7F-B334-37DCAD3F10E8Q31144876-8E318915-05AE-41CA-B59C-899A1EBDAB90Q33653485-42057181-66B6-4559-B692-007824665502Q35226511-C4BF7C0F-2FE0-46F6-90E4-EBC424791AACQ35296661-5C67719D-36D1-40C0-98C5-CE072F5ED54BQ35634132-CBF67139-F10E-4367-ABA0-1B427AC04F7FQ35651085-07A18515-15FD-4CE0-BB00-D13CC9F7295AQ36460449-06C6D694-E0E5-4543-AF89-38E0C134D9D8Q36589179-7AAD497B-6E04-484D-8128-6ADE3EBCD27FQ36757131-2C40251E-0A4C-4C00-8ED7-4E748DB87FBFQ37107332-FE82D1E6-A7A1-4E43-AEA2-91BAE2409587Q37109089-8ECF7B5D-8208-48CA-A48E-0526647605DDQ37224420-8FC7C70D-58E7-43F4-ABBE-1B83777109CFQ37587945-A577DB54-E9CD-4B0D-A690-98B73416C9FFQ37625385-8B9AED57-B72A-454A-AAD7-EB46B61C1C7FQ37688850-07E58270-C075-4B58-86E3-2AC0EC9998E1Q38211241-A1296EBF-1DCA-4E04-A725-CEF0D516F7B0Q38720538-7A9BEBDC-8E05-40B8-8BC2-837B2B7ED5BAQ38793621-0918289C-C801-4D71-9254-855D93D83018Q38918317-77A7974F-9921-4D2A-B154-5EF480924694Q39064497-87BD38A3-0171-4ED9-A714-94997A7E5FC9Q40675932-7E830206-115B-4BE9-BC2F-B31D431F091DQ41441101-17A07D2D-8E41-4799-BFD7-6653615CEE9FQ42362802-8804A2C8-06C1-47AE-A369-AE1DBACC3B23Q47141309-0FC0A83C-0ADF-4DCE-9F99-3F1BAEB1189FQ54968953-914E538E-FCBC-4DA5-9DF7-DBD12C82731DQ55379548-9044E48F-CA0F-48C7-A99E-BA2DA033DC24
P2860
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@ast
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@en
type
label
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@ast
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@en
prefLabel
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@ast
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@en
P2093
P2860
P1476
A phase I clinical trial of Ad ...... h recurrent gynecologic cancer
@en
P2093
Igor Dmitriev
Janis P O'Malley
Kenneth H Kim
Kurt R Zinn
Meredith A Preuss
Minghui Wang
Raymond D Harris
Ronald D Alvarez
Rosemarie Aurigemma
Souheil Saddekni
P2860
P304
P356
10.1158/1078-0432.CCR-11-2852
P407
P577
2012-04-17T00:00:00Z